Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjögren’s disease

By Public Technologies
  • Amgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic Sjögren's disease.
  • The trial met its primary goal, showing a meaningful reduction in overall systemic disease activity that emerged quickly then held through 48 weeks.
  • Safety was broadly consistent with expectations, with mostly mild-to-moderate side effects and low discontinuation rates.
  • Detailed results have not yet been presented; Amgen plans to disclose the full dataset at an upcoming medical meeting.
  • A second Phase 3 study in a different Sjögren's population is expected to finish in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53425) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.